ChemicalName,ChemicalID,DiseaseName,DiseaseID,DirectEvidence,InferenceGeneSymbol,InferenceScore
06-Paris-LA-66 protocol,C046983,Precursor Cell Lymphoblastic Leukemia-Lymphoma,MESH:D054198,therapeutic,,
10074-G5,C534883,Adenocarcinoma,MESH:D000230,,MYC,4.07
10074-G5,C534883,Adenocarcinoma of Lung,MESH:D000077192,,MYC,4.3
10074-G5,C534883,Alopecia,MESH:D000505,,AR,4.5
10074-G5,C534883,Androgen-Insensitivity Syndrome,MESH:D013734,,AR,6.87
10074-G5,C534883,Astrocytoma,MESH:D001254,,AR,4.94
10074-G5,C534883,Autistic Disorder,MESH:D001321,,AR,3.93
10074-G5,C534883,Breast Neoplasms,MESH:D001943,,AR,3.42
10074-G5,C534883,"Breast Neoplasms, Male",MESH:D018567,,AR,5.89
10074-G5,C534883,"Bulbospinal neuronopathy, X-linked recessive",MESH:C537017,,AR,6.87
10074-G5,C534883,Burkitt Lymphoma,MESH:D002051,,MYC,5.11
10074-G5,C534883,Carcinoma,MESH:D002277,,MYC,4.09
10074-G5,C534883,"Carcinoma, Ductal",MESH:D044584,,MYC,5.59
10074-G5,C534883,"Carcinoma, Hepatocellular",MESH:D006528,,AR,7.48
10074-G5,C534883,"Carcinoma, Hepatocellular",MESH:D006528,,MYC,7.48
10074-G5,C534883,"Carcinoma, Merkel Cell",MESH:D015266,,MYC,6.14
10074-G5,C534883,"Carcinoma, Non-Small-Cell Lung",MESH:D002289,,MYC,4.19
10074-G5,C534883,"Carcinoma, Squamous Cell",MESH:D002294,,MYC,4.21
10074-G5,C534883,"Cardiomyopathy, Hypertrophic",MESH:D002312,,MYC,4.75
10074-G5,C534883,"Cell Transformation, Neoplastic",MESH:D002471,,MYC,3.99
10074-G5,C534883,Chromosome Breakage,MESH:D019457,,MYC,4.28
10074-G5,C534883,Cleft Lip,MESH:D002971,,MYC,5.03
10074-G5,C534883,Cleft Palate,MESH:D002972,,MYC,4.61
10074-G5,C534883,Colonic Neoplasms,MESH:D003110,,MYC,3.99
10074-G5,C534883,Colorectal Neoplasms,MESH:D015179,,MYC,3.91
10074-G5,C534883,"Diabetes, Gestational",MESH:D016640,,AR,5.06
10074-G5,C534883,"Disease Models, Animal",MESH:D004195,,MYC,3.83
10074-G5,C534883,Disease Progression,MESH:D018450,,MYC,4.11
10074-G5,C534883,Endometrial Neoplasms,MESH:D016889,,MYC,4.54
10074-G5,C534883,Ependymoma,MESH:D004806,,EPHB2,6.61
10074-G5,C534883,Fatty Liver,MESH:D005234,,MYC,3.88
10074-G5,C534883,"Genital Diseases, Male",MESH:D005832,,AR,5.02
10074-G5,C534883,Glioblastoma,MESH:D005909,,MYC,4.4
10074-G5,C534883,Hemangiosarcoma,MESH:D006394,,MYC,4.97
10074-G5,C534883,Hypertension,MESH:D006973,,AR,3.39
10074-G5,C534883,"Hypertrophy, Left Ventricular",MESH:D017379,,MYC,4.47
10074-G5,C534883,"Hypospadias 1, X-Linked",MESH:C567482,,AR,6.87
10074-G5,C534883,"Infertility, Female",MESH:D007247,,AR,4.51
10074-G5,C534883,"Infertility, Male",MESH:D007248,,AR,4.27
10074-G5,C534883,Insulin Resistance,MESH:D007333,,AR,3.92
10074-G5,C534883,Leukemia,MESH:D007938,,AR,4.33
10074-G5,C534883,"Leukemia, Myeloid, Acute",MESH:D015470,,MYC,4.18
10074-G5,C534883,"Liver Cirrhosis, Experimental",MESH:D008106,,MYC,3.51
10074-G5,C534883,Liver Neoplasms,MESH:D008113,,MYC,3.83
10074-G5,C534883,"Liver Neoplasms, Experimental",MESH:D008114,,MYC,3.93
10074-G5,C534883,Lung Neoplasms,MESH:D008175,,AR,7.9
10074-G5,C534883,Lung Neoplasms,MESH:D008175,,MYC,7.9
10074-G5,C534883,"Lymphoma, Large B-Cell, Diffuse",MESH:D016403,,MYC,4.8
10074-G5,C534883,Medulloblastoma,MESH:D008527,,MYC,4.79
10074-G5,C534883,Myelodysplastic Syndromes,MESH:D009190,,MYC,4.79
10074-G5,C534883,Neoplasm Metastasis,MESH:D009362,,MYC,3.88
10074-G5,C534883,"Neoplasm Recurrence, Local",MESH:D009364,,AR,4.85
10074-G5,C534883,Neoplasms,MESH:D009369,,MYC,3.87
10074-G5,C534883,Neuroblastoma,MESH:D009447,,MYC,4.59
10074-G5,C534883,Neuroectodermal Tumors,MESH:D017599,,MYC,5.79
10074-G5,C534883,Osteosarcoma,MESH:D012516,,MYC,4.71
10074-G5,C534883,Ovarian Neoplasms,MESH:D010051,,MYC,4.17
10074-G5,C534883,Pancreatic Neoplasms,MESH:D010190,,MYC,4.2
10074-G5,C534883,Pheochromocytoma,MESH:D010673,,MAX,6.23
10074-G5,C534883,"Polycystic Kidney, Autosomal Dominant",MESH:D016891,,MYC,5.84
10074-G5,C534883,PROSTATE CANCER/BRAIN CANCER SUSCEPTIBILITY,OMIM:603688,,EPHB2,7.81
10074-G5,C534883,Prostatic Intraepithelial Neoplasia,MESH:D019048,,AR,5.26
10074-G5,C534883,Prostatic Neoplasms,MESH:D011471,,AR,7.31
10074-G5,C534883,Prostatic Neoplasms,MESH:D011471,,MYC,7.31
10074-G5,C534883,"Prostatic Neoplasms, Castration-Resistant",MESH:D064129,,AR,5.18
10074-G5,C534883,Stomach Neoplasms,MESH:D013274,,MYC,3.87
10074-G5,C534883,Urinary Bladder Neoplasms,MESH:D001749,,MYC,3.99
10074-G5,C534883,Uterine Cervical Neoplasms,MESH:D002583,,MYC,4.73
10074-G5,C534883,Wilms Tumor,MESH:D009396,,MAX,6.02
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Adenocarcinoma,MESH:D000230,,KCNQ1,4.69
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Amphetamine-Related Disorders,MESH:D019969,,FOS,4.15
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Amyotrophic lateral sclerosis 1,MESH:C531617,,FOS,4.62
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Anxiety Disorders,MESH:D001008,,FOS,3.72
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,"Arthritis, Juvenile",MESH:D001171,,FOS,4.13
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,"Atrial Fibrillation, Familial, 3",MESH:C563817,,KCNQ1,7.56
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Beckwith-Wiedemann Syndrome,MESH:D001506,,KCNQ1,6.76
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Brain Diseases,MESH:D001927,,KCNQ2,4.87
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Brain Injuries,MESH:D001930,,FOS,3.74
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Breast Neoplasms,MESH:D001943,,FOS,3.19
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,"Carcinoma, Hepatocellular",MESH:D006528,,FOS,3.3
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,"Carcinoma, Ovarian Epithelial",MESH:D000077216,,FOS,4.72
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,"Cell Transformation, Neoplastic",MESH:D002471,,FOS,3.68
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,"Cholestasis, Extrahepatic",MESH:D001651,,FOS,4.72
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Cocaine-Related Disorders,MESH:D019970,,FOS,3.58
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 7,OMIM:613720,,KCNQ2,7.66
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Developmental Disabilities,MESH:D002658,,KCNQ2,5.5
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,"Diabetes Mellitus, Type 2",MESH:D003924,,KCNQ1,4.6
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,"Disease Models, Animal",MESH:D004195,,FOS,3.52
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Endometriosis,MESH:D004715,,FOS,3.99
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Epilepsy,MESH:D004827,,FOS,9.06
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Epilepsy,MESH:D004827,,KCNQ2,9.06
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,"Epilepsy, Benign Neonatal",MESH:D020936,,KCNQ2,7.31
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Fibrous Dysplasia of Bone,MESH:D005357,,FOS,5.73
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,"Hearing Loss, Noise-Induced",MESH:D006317,,KCNQ1,5.8
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Heat Stroke,MESH:D018883,,FOS,4.82
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Hemorrhage,MESH:D006470,,FOS,3.67
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Hyperalgesia,MESH:D006930,,FOS,3.45
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Hyperkinesis,MESH:D006948,marker/mechanism,,
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Hyperkinesis,MESH:D006948,,FOS,3.58
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Hypertension,MESH:D006973,,FOS,3.17
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,"Infarction, Middle Cerebral Artery",MESH:D020244,,FOS,4.38
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Intestinal Neoplasms,MESH:D007414,,KCNQ1,5.48
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Jervell-Lange Nielsen Syndrome,MESH:D029593,,KCNQ1,7.22
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,"Liver Cirrhosis, Experimental",MESH:D008106,,FOS,3.2
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Long QT Syndrome,MESH:D008133,,KCNQ1,4.86
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Lung Neoplasms,MESH:D008175,,FOS,3.42
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Nervous System Diseases,MESH:D009422,,FOS,8.37
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Nervous System Diseases,MESH:D009422,,KCNQ2,8.37
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Neurodevelopmental Disorders,MESH:D065886,,KCNQ2,5.32
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Neurotoxicity Syndromes,MESH:D020258,,FOS,3.77
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Obesity,MESH:D009765,,FOS,3.66
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Reperfusion Injury,MESH:D015427,,FOS,3.86
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Romano-Ward Syndrome,MESH:D029597,,KCNQ1,7.22
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Seizures,MESH:D012640,marker/mechanism,,
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Seizures,MESH:D012640,,FOS,6.39
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Seizures,MESH:D012640,,KCNQ2,6.39
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,"SEIZURES, BENIGN FAMILIAL NEONATAL, 1",OMIM:121200,,KCNQ2,7.66
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,"SEIZURES, BENIGN FAMILIAL NEONATAL, 2",OMIM:121201,,KCNQ3,7.77
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Short QT Syndrome 2,MESH:C566505,,KCNQ1,7.56
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Status Epilepticus,MESH:D013226,,FOS,3.85
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Substance Withdrawal Syndrome,MESH:D013375,,FOS,3.59
"10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone",C112297,Trigeminal Neuralgia,MESH:D014277,,FOS,4.98
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,"Abnormalities, Drug-Induced",MESH:D000014,,EPHX1,5.15
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,Acute Lung Injury,MESH:D055371,,EPHX1,5.28
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,Amphetamine-Related Disorders,MESH:D019969,,EPHX1,5.44
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,Autism Spectrum Disorder,MESH:D000067877,,EPHX1,4.91
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,Carcinoma,MESH:D002277,,EPHX1,5.06
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,"Carcinoma, Hepatocellular",MESH:D006528,,EPHX1,4.57
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,Chemical and Drug Induced Liver Injury,MESH:D056486,,EPHX1,4.12
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,Fever,MESH:D005334,,EPHX1,4.92
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,"Hypercholanemia, Familial",MESH:C564336,,EPHX1,7.58
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,"Leukemia, Myeloid, Acute",MESH:D015470,,EPHX1,5.16
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,Lung Neoplasms,MESH:D008175,,EPHX1,4.7
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,Lymphoma,MESH:D008223,,EPHX1,5.59
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,"Lymphoma, Non-Hodgkin",MESH:D008228,,EPHX1,5.43
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,"Mammary Neoplasms, Animal",MESH:D015674,,EPHX1,5.23
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,"Mammary Neoplasms, Experimental",MESH:D008325,,EPHX1,5.04
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,"Mesothelioma, Malignant",MESH:D000086002,,EPHX1,5.48
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,"Micronuclei, Chromosome-Defective",MESH:D048629,,EPHX1,5.1
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,Multiple Myeloma,MESH:D009101,,EPHX1,5.39
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,Myocardial Ischemia,MESH:D017202,,EPHX1,4.94
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,Precursor Cell Lymphoblastic Leukemia-Lymphoma,MESH:D054198,,EPHX1,5.41
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,Pre-Eclampsia,MESH:D011225,,EPHX1,5.77
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,Prostatic Neoplasms,MESH:D011471,,EPHX1,4.52
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,"Pulmonary Disease, Chronic Obstructive",MESH:D029424,,EPHX1,5.55
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,Pulmonary Emphysema,MESH:D011656,,EPHX1,6.35
"10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide",C004822,Skin Neoplasms,MESH:D012878,,EPHX1,5.19
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Acute Kidney Injury,MESH:D058186,,CYP2C19,4.1
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Adrenocortical Carcinoma,MESH:D018268,,ABCB1,5.4
"10,11-dihydro-10-hydroxycarbamazepine",C039775,"Arthritis, Experimental",MESH:D001169,,ABCB1,4.61
"10,11-dihydro-10-hydroxycarbamazepine",C039775,"Arthritis, Rheumatoid",MESH:D001172,,ABCB1,4.25
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Atrial Fibrillation,MESH:D001281,,CYP2C19,4.51
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Autism Spectrum Disorder,MESH:D000067877,,ABCB1,9.28
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Autism Spectrum Disorder,MESH:D000067877,,CYP2C19,9.28
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Breast Neoplasms,MESH:D001943,,ABCB1,3.64
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Carcinoma,MESH:D002277,,ABCB1,4.24
"10,11-dihydro-10-hydroxycarbamazepine",C039775,"Carcinoma, Hepatocellular",MESH:D006528,,ABCB1,3.75
"10,11-dihydro-10-hydroxycarbamazepine",C039775,"Carcinoma, Non-Small-Cell Lung",MESH:D002289,,ABCB1,4.34
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Cardiovascular Diseases,MESH:D002318,,CYP2C19,4.54
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Chemical and Drug Induced Liver Injury,MESH:D056486,,ABCB1,6.73
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Chemical and Drug Induced Liver Injury,MESH:D056486,,CYP2C19,6.73
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Colorectal Neoplasms,MESH:D015179,,ABCB1,4.06
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Disease Progression,MESH:D018450,,ABCB1,4.26
"10,11-dihydro-10-hydroxycarbamazepine",C039775,"Drug Metabolism, Poor, CYP2C19-Related",MESH:C563703,,CYP2C19,7.4
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Drug-Related Side Effects and Adverse Reactions,MESH:D064420,,ABCB1,3.8
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Epilepsy,MESH:D004827,therapeutic,,
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Epilepsy,MESH:D004827,,ABCB1,4.36
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Escherichia coli Infections,MESH:D004927,,ABCB1,5.17
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Esophageal Neoplasms,MESH:D004938,,ABCB1,4.59
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Genetic Predisposition to Disease,MESH:D020022,,ABCB1,12.56
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Genetic Predisposition to Disease,MESH:D020022,,CYP2C19,12.56
"10,11-dihydro-10-hydroxycarbamazepine",C039775,"Heart Defects, Congenital",MESH:D006330,,ABCB1,4.58
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Hematologic Neoplasms,MESH:D019337,,ABCB1,5.4
"10,11-dihydro-10-hydroxycarbamazepine",C039775,"Hypotension, Orthostatic",MESH:D007024,,ABCB1,4.58
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Inflammatory Bowel Disease 13,MESH:C567384,,ABCB1,7.1
"10,11-dihydro-10-hydroxycarbamazepine",C039775,"Kidney Failure, Chronic",MESH:D007676,,CYP2C19,4.9
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Kidney Neoplasms,MESH:D007680,,ABCB1,4.55
"10,11-dihydro-10-hydroxycarbamazepine",C039775,"Liver Cirrhosis, Experimental",MESH:D008106,,ABCB1,3.65
"10,11-dihydro-10-hydroxycarbamazepine",C039775,"Lymphoma, Large B-Cell, Diffuse",MESH:D016403,,ABCB1,4.95
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Marijuana Abuse,MESH:D002189,,ABCB1,5.68
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Mental Disorders,MESH:D001523,,ABCB1,4.49
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Nausea,MESH:D009325,,ABCB1,3.96
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Neoplasm Metastasis,MESH:D009362,,ABCB1,4.03
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Neoplasms,MESH:D009369,,ABCB1,4.02
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Nervous System Diseases,MESH:D009422,,ABCB1,4.15
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Neuroblastoma,MESH:D009447,,ABCB1,4.74
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Neurotoxicity Syndromes,MESH:D020258,,ABCB1,4.23
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Neutropenia,MESH:D009503,,ABCB1,4.38
"10,11-dihydro-10-hydroxycarbamazepine",C039775,"Pain, Postoperative",MESH:D010149,,ABCB1,4.72
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Parkinson Disease,MESH:D010300,,ABCB1,4.26
"10,11-dihydro-10-hydroxycarbamazepine",C039775,"Parkinson Disease, Secondary",MESH:D010302,,ABCB1,4.56
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Peripheral Nervous System Diseases,MESH:D010523,,ABCB1,4.23
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Poisoning,MESH:D011041,,ABCB1,4.02
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Precursor Cell Lymphoblastic Leukemia-Lymphoma,MESH:D054198,,ABCB1,4.59
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Primary Ovarian Insufficiency,MESH:D016649,,CYP2C19,6.15
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Prostatic Neoplasms,MESH:D011471,,CYP2C19,4.0
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Squamous Cell Carcinoma of Head and Neck,MESH:D000077195,,ABCB1,4.92
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Thrombosis,MESH:D013927,,CYP2C19,4.62
"10,11-dihydro-10-hydroxycarbamazepine",C039775,"Translocation, Genetic",MESH:D014178,,ABCB1,5.71
"10,11-dihydro-10-hydroxycarbamazepine",C039775,Vomiting,MESH:D014839,,ABCB1,3.99
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,Alopecia,MESH:D000505,,AR,5.19
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,Androgen-Insensitivity Syndrome,MESH:D013734,,AR,7.56
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,Astrocytoma,MESH:D001254,,AR,5.63
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,Autistic Disorder,MESH:D001321,,AR,4.61
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,Breast Neoplasms,MESH:D001943,,AR,4.09
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,"Breast Neoplasms, Male",MESH:D018567,,AR,6.59
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,"Bulbospinal neuronopathy, X-linked recessive",MESH:C537017,,AR,7.56
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,"Carcinoma, Hepatocellular",MESH:D006528,,AR,4.21
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,"Diabetes, Gestational",MESH:D016640,,AR,5.75
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,"Genital Diseases, Male",MESH:D005832,,AR,5.71
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,Hypertension,MESH:D006973,,AR,4.07
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,"Hypospadias 1, X-Linked",MESH:C567482,,AR,7.56
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,"Infertility, Female",MESH:D007247,,AR,5.2
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,"Infertility, Male",MESH:D007248,,AR,4.96
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,Insulin Resistance,MESH:D007333,,AR,4.61
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,Leukemia,MESH:D007938,,AR,5.02
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,Lung Neoplasms,MESH:D008175,,AR,4.34
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,"Neoplasm Recurrence, Local",MESH:D009364,,AR,5.55
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,Prostatic Intraepithelial Neoplasia,MESH:D019048,,AR,5.95
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,Prostatic Neoplasms,MESH:D011471,,AR,4.15
"10,11-dihydro-5H-dibenzo(a,d)cycloheptene",C515697,"Prostatic Neoplasms, Castration-Resistant",MESH:D064129,,AR,5.88
"10,11-dihydroxy-N-n-propylnorapomorphine",C425777,Hyperkinesis,MESH:D006948,marker/mechanism,,
"10,12-octadecadienoic acid",C094849,Acute Kidney Injury,MESH:D058186,,PPARG,3.66
"10,12-octadecadienoic acid",C094849,Acute Lung Injury,MESH:D055371,,CASP3,10.12
"10,12-octadecadienoic acid",C094849,Acute Lung Injury,MESH:D055371,,PPARG,10.12
"10,12-octadecadienoic acid",C094849,Adenocarcinoma,MESH:D000230,,PPARG,4.07
"10,12-octadecadienoic acid",C094849,Alzheimer Disease,MESH:D000544,,CASP3,9.82
"10,12-octadecadienoic acid",C094849,Alzheimer Disease,MESH:D000544,,PPARG,9.82
"10,12-octadecadienoic acid",C094849,Antiphospholipid Syndrome,MESH:D016736,,PPARG,5.8
"10,12-octadecadienoic acid",C094849,Atherosclerosis,MESH:D050197,,PPARG,4.16
"10,12-octadecadienoic acid",C094849,Barrett Esophagus,MESH:D001471,,PPARG,5.38
"10,12-octadecadienoic acid",C094849,Brain Ischemia,MESH:D002545,,CASP3,3.89
"10,12-octadecadienoic acid",C094849,Calcinosis,MESH:D002114,,CASP3,4.34
"10,12-octadecadienoic acid",C094849,"Carcinoma, Hepatocellular",MESH:D006528,,PPARG,3.61
"10,12-octadecadienoic acid",C094849,Carotid Intimal Medial Thickness 1,MESH:C563733,,PPARG,6.15
"10,12-octadecadienoic acid",C094849,Cerebral Hemorrhage,MESH:D002543,,CASP3,4.03
"10,12-octadecadienoic acid",C094849,Chronobiology Disorders,MESH:D021081,,PPARG,5.56
"10,12-octadecadienoic acid",C094849,"Colitis, Ulcerative",MESH:D003093,,CASP3,4.08
"10,12-octadecadienoic acid",C094849,Colonic Neoplasms,MESH:D003110,,PPARG,4.0
"10,12-octadecadienoic acid",C094849,Colorectal Neoplasms,MESH:D015179,,PPARG,3.92
"10,12-octadecadienoic acid",C094849,Copper-Overload Cirrhosis,MESH:C566858,,CASP3,5.3
"10,12-octadecadienoic acid",C094849,Crohn Disease,MESH:D003424,,PPARG,4.76
"10,12-octadecadienoic acid",C094849,Cryptorchidism,MESH:D003456,,CASP3,4.76
"10,12-octadecadienoic acid",C094849,Diabetes Mellitus,MESH:D003920,,PPARG,4.36
"10,12-octadecadienoic acid",C094849,"Diabetes Mellitus, Experimental",MESH:D003921,,CASP3,9.67
"10,12-octadecadienoic acid",C094849,"Diabetes Mellitus, Experimental",MESH:D003921,,PPARG,9.67
"10,12-octadecadienoic acid",C094849,"Diabetes Mellitus, Type 2",MESH:D003924,,CASP3,9.03
"10,12-octadecadienoic acid",C094849,"Diabetes Mellitus, Type 2",MESH:D003924,,PPARG,9.03
"10,12-octadecadienoic acid",C094849,Diabetic Angiopathies,MESH:D003925,,CASP3,4.69
"10,12-octadecadienoic acid",C094849,Diabetic Nephropathies,MESH:D003928,,PPARG,4.42
"10,12-octadecadienoic acid",C094849,Diabetic Neuropathies,MESH:D003929,,CASP3,4.45
"10,12-octadecadienoic acid",C094849,Diabetic Retinopathy,MESH:D003930,,CASP3,4.67
"10,12-octadecadienoic acid",C094849,Dyslipidemias,MESH:D050171,,PPARG,4.39
"10,12-octadecadienoic acid",C094849,Edema,MESH:D004487,,CASP3,3.25
"10,12-octadecadienoic acid",C094849,Glomerulonephritis,MESH:D005921,,PPARG,4.49
"10,12-octadecadienoic acid",C094849,Heart Failure,MESH:D006333,,PPARG,3.78
"10,12-octadecadienoic acid",C094849,Heart Valve Diseases,MESH:D006349,,CASP3,4.53
"10,12-octadecadienoic acid",C094849,"Hepatitis, Chronic",MESH:D006521,,CASP3,4.61
"10,12-octadecadienoic acid",C094849,Hypertension,MESH:D006973,,PPARG,3.47
"10,12-octadecadienoic acid",C094849,Inflammation,MESH:D007249,,PPARG,3.58
"10,12-octadecadienoic acid",C094849,Insulin Resistance,MESH:D007333,,PPARG,4.0
"10,12-octadecadienoic acid",C094849,Ischemia,MESH:D007511,,PPARG,4.44
"10,12-octadecadienoic acid",C094849,"Leukemia, Promyelocytic, Acute",MESH:D015473,,PPARG,4.61
"10,12-octadecadienoic acid",C094849,Leukostasis,MESH:D018921,,PPARG,5.98
"10,12-octadecadienoic acid",C094849,Lipidoses,MESH:D008064,,PPARG,4.46
"10,12-octadecadienoic acid",C094849,"Lipodystrophy, Familial Partial",MESH:D052496,,PPARG,5.91
"10,12-octadecadienoic acid",C094849,Liver Neoplasms,MESH:D008113,,PPARG,3.84
"10,12-octadecadienoic acid",C094849,"Lymphoma, T-Cell",MESH:D016399,,PPARG,5.06
"10,12-octadecadienoic acid",C094849,Melanoma,MESH:D008545,,PPARG,3.98
"10,12-octadecadienoic acid",C094849,Metabolic Diseases,MESH:D008659,,PPARG,5.13
"10,12-octadecadienoic acid",C094849,Mycoplasma Infections,MESH:D009175,,CASP3,5.39
"10,12-octadecadienoic acid",C094849,Myocardial Infarction,MESH:D009203,,CASP3,3.43
"10,12-octadecadienoic acid",C094849,Myocardial Reperfusion Injury,MESH:D015428,,CASP3,3.92
"10,12-octadecadienoic acid",C094849,Nerve Degeneration,MESH:D009410,,CASP3,8.44
"10,12-octadecadienoic acid",C094849,Nerve Degeneration,MESH:D009410,,PPARG,8.44
"10,12-octadecadienoic acid",C094849,Nervous System Diseases,MESH:D009422,,CASP3,3.59
"10,12-octadecadienoic acid",C094849,Neurotoxicity Syndromes,MESH:D020258,,CASP3,3.68
"10,12-octadecadienoic acid",C094849,Non-alcoholic Fatty Liver Disease,MESH:D065626,,PPARG,4.26
"10,12-octadecadienoic acid",C094849,Obesity,MESH:D009765,,PPARG,3.98
"10,12-octadecadienoic acid",C094849,Osteoarthritis,MESH:D010003,,PPARG,4.41
"10,12-octadecadienoic acid",C094849,Pancreatic Neoplasms,MESH:D010190,,PPARG,4.2
"10,12-octadecadienoic acid",C094849,Pituitary ACTH Hypersecretion,MESH:D047748,,PPARG,5.98
"10,12-octadecadienoic acid",C094849,Pneumoconiosis,MESH:D011009,,SCD5,6.54
"10,12-octadecadienoic acid",C094849,"Polycystic Kidney, Autosomal Dominant",MESH:D016891,,PPARG,5.85
"10,12-octadecadienoic acid",C094849,Pre-Eclampsia,MESH:D011225,,PPARG,4.8
"10,12-octadecadienoic acid",C094849,Psoriasis,MESH:D011565,,PPARG,4.5
"10,12-octadecadienoic acid",C094849,Renal Insufficiency,MESH:D051437,,PPARG,3.98
"10,12-octadecadienoic acid",C094849,Reperfusion Injury,MESH:D015427,,CASP3,9.71
"10,12-octadecadienoic acid",C094849,Reperfusion Injury,MESH:D015427,,PPARG,9.71
"10,12-octadecadienoic acid",C094849,Retinal Detachment,MESH:D012163,,CASP3,5.09
"10,12-octadecadienoic acid",C094849,Sepsis,MESH:D018805,,CASP3,4.03
"10,12-octadecadienoic acid",C094849,Spinal Cord Injuries,MESH:D013119,,CASP3,4.48
"10,12-octadecadienoic acid",C094849,Status Epilepticus,MESH:D013226,,CASP3,3.76
"10,12-octadecadienoic acid",C094849,Stomach Neoplasms,MESH:D013274,,PPARG,3.87
"10,12-octadecadienoic acid",C094849,Subarachnoid Hemorrhage,MESH:D013345,,CASP3,11.9
"10,12-octadecadienoic acid",C094849,Subarachnoid Hemorrhage,MESH:D013345,,PPARG,11.9
"10,12-octadecadienoic acid",C094849,"Thyroid cancer, follicular",MESH:C572845,,PPARG,5.53
"10,12-octadecadienoic acid",C094849,Thyroid Neoplasms,MESH:D013964,,PPARG,4.49
10-(2-pyrazolylethoxy)camptothecin,C534422,Acute Lung Injury,MESH:D055371,,CASP3,4.1
10-(2-pyrazolylethoxy)camptothecin,C534422,Adenocarcinoma,MESH:D000230,,CASP8,4.32
10-(2-pyrazolylethoxy)camptothecin,C534422,Alzheimer Disease,MESH:D000544,,CASP3,4.01
10-(2-pyrazolylethoxy)camptothecin,C534422,Autoimmune Lymphoproliferative Syndrome,MESH:D056735,,CASP8,6.22
10-(2-pyrazolylethoxy)camptothecin,C534422,Brain Ischemia,MESH:D002545,,CASP3,4.1
10-(2-pyrazolylethoxy)camptothecin,C534422,Breast Neoplasms,MESH:D001943,,CASP8,3.74
10-(2-pyrazolylethoxy)camptothecin,C534422,Calcinosis,MESH:D002114,,CASP3,4.54
10-(2-pyrazolylethoxy)camptothecin,C534422,"Carcinoma, Hepatocellular",MESH:D006528,,CASP8,3.85
10-(2-pyrazolylethoxy)camptothecin,C534422,"Carcinoma, Non-Small-Cell Lung",MESH:D002289,,CASP8,4.44
10-(2-pyrazolylethoxy)camptothecin,C534422,Cerebral Hemorrhage,MESH:D002543,,CASP3,11.47
10-(2-pyrazolylethoxy)camptothecin,C534422,Cerebral Hemorrhage,MESH:D002543,,CASP8,11.47
10-(2-pyrazolylethoxy)camptothecin,C534422,"Colitis, Ulcerative",MESH:D003093,,CASP3,4.28
10-(2-pyrazolylethoxy)camptothecin,C534422,Colorectal Neoplasms,MESH:D015179,,CASP8,4.16
10-(2-pyrazolylethoxy)camptothecin,C534422,Copper-Overload Cirrhosis,MESH:C566858,,CASP3,5.5
10-(2-pyrazolylethoxy)camptothecin,C534422,Cryptorchidism,MESH:D003456,,CASP3,4.96
10-(2-pyrazolylethoxy)camptothecin,C534422,"Dermatitis, Allergic Contact",MESH:D017449,,CASP8,4.35
10-(2-pyrazolylethoxy)camptothecin,C534422,"Dermatitis, Contact",MESH:D003877,,CASP8,4.58
10-(2-pyrazolylethoxy)camptothecin,C534422,"Diabetes Mellitus, Experimental",MESH:D003921,,CASP3,3.96
10-(2-pyrazolylethoxy)camptothecin,C534422,"Diabetes Mellitus, Type 2",MESH:D003924,,CASP3,9.94
10-(2-pyrazolylethoxy)camptothecin,C534422,"Diabetes Mellitus, Type 2",MESH:D003924,,CASP8,9.94
10-(2-pyrazolylethoxy)camptothecin,C534422,Diabetic Angiopathies,MESH:D003925,,CASP3,4.9
10-(2-pyrazolylethoxy)camptothecin,C534422,Diabetic Neuropathies,MESH:D003929,,CASP3,4.65
10-(2-pyrazolylethoxy)camptothecin,C534422,Diabetic Retinopathy,MESH:D003930,,CASP3,4.87
10-(2-pyrazolylethoxy)camptothecin,C534422,Edema,MESH:D004487,,CASP3,8.91
10-(2-pyrazolylethoxy)camptothecin,C534422,Edema,MESH:D004487,,CASP8,8.91
10-(2-pyrazolylethoxy)camptothecin,C534422,Esophageal Neoplasms,MESH:D004938,,CASP8,4.69
10-(2-pyrazolylethoxy)camptothecin,C534422,Heart Valve Diseases,MESH:D006349,,CASP3,4.73
10-(2-pyrazolylethoxy)camptothecin,C534422,"Hepatitis, Chronic",MESH:D006521,,CASP3,4.82
10-(2-pyrazolylethoxy)camptothecin,C534422,Lung Neoplasms,MESH:D008175,,CASP8,3.98
10-(2-pyrazolylethoxy)camptothecin,C534422,Melanoma,MESH:D008545,,CASP8,4.23
10-(2-pyrazolylethoxy)camptothecin,C534422,Mitochondrial Diseases,MESH:D028361,,CASP8,5.04
10-(2-pyrazolylethoxy)camptothecin,C534422,Mycoplasma Infections,MESH:D009175,,CASP3,5.59
10-(2-pyrazolylethoxy)camptothecin,C534422,Myocardial Infarction,MESH:D009203,,CASP3,3.63
10-(2-pyrazolylethoxy)camptothecin,C534422,Myocardial Reperfusion Injury,MESH:D015428,,CASP3,11.11
10-(2-pyrazolylethoxy)camptothecin,C534422,Myocardial Reperfusion Injury,MESH:D015428,,CASP8,11.11
10-(2-pyrazolylethoxy)camptothecin,C534422,Nerve Degeneration,MESH:D009410,,CASP3,3.59
10-(2-pyrazolylethoxy)camptothecin,C534422,Nervous System Diseases,MESH:D009422,,CASP3,3.79
10-(2-pyrazolylethoxy)camptothecin,C534422,Neurotoxicity Syndromes,MESH:D020258,,CASP3,3.88
10-(2-pyrazolylethoxy)camptothecin,C534422,Papillomavirus Infections,MESH:D030361,,CASP8,6.3
10-(2-pyrazolylethoxy)camptothecin,C534422,Precursor Cell Lymphoblastic Leukemia-Lymphoma,MESH:D054198,,CASP8,4.69
10-(2-pyrazolylethoxy)camptothecin,C534422,"Prostate cancer, familial",MESH:C537243,,CASP8,5.15
10-(2-pyrazolylethoxy)camptothecin,C534422,Reperfusion Injury,MESH:D015427,,CASP3,10.62
10-(2-pyrazolylethoxy)camptothecin,C534422,Reperfusion Injury,MESH:D015427,,CASP8,10.62
10-(2-pyrazolylethoxy)camptothecin,C534422,Retinal Detachment,MESH:D012163,,CASP3,5.3
10-(2-pyrazolylethoxy)camptothecin,C534422,Sepsis,MESH:D018805,,CASP3,4.23
10-(2-pyrazolylethoxy)camptothecin,C534422,Skin Neoplasms,MESH:D012878,,CASP8,4.47
10-(2-pyrazolylethoxy)camptothecin,C534422,Spinal Cord Injuries,MESH:D013119,,CASP3,4.68
10-(2-pyrazolylethoxy)camptothecin,C534422,Squamous Cell Carcinoma of Head and Neck,MESH:D000077195,,CASP8,5.03
10-(2-pyrazolylethoxy)camptothecin,C534422,Status Epilepticus,MESH:D013226,,CASP3,10.58
10-(2-pyrazolylethoxy)camptothecin,C534422,Status Epilepticus,MESH:D013226,,CASP8,10.58
10-(2-pyrazolylethoxy)camptothecin,C534422,Stomach Neoplasms,MESH:D013274,,CASP8,4.12
10-(2-pyrazolylethoxy)camptothecin,C534422,Subarachnoid Hemorrhage,MESH:D013345,,CASP3,4.64
10-(2-pyrazolylethoxy)camptothecin,C534422,Uterine Cervical Neoplasms,MESH:D002583,,CASP8,4.98
103D5R,C496879,Acute Kidney Injury,MESH:D058186,,VEGFA,3.27
103D5R,C496879,Adenocarcinoma,MESH:D000230,,AKT1,7.89
103D5R,C496879,Adenocarcinoma,MESH:D000230,,VEGFA,7.89
103D5R,C496879,Adenomatous Polyposis Coli,MESH:D011125,,AKT1,4.65
103D5R,C496879,Alzheimer Disease,MESH:D000544,,VEGFA,3.82
103D5R,C496879,Amphetamine-Related Disorders,MESH:D019969,,AKT1,3.93
103D5R,C496879,Anaplasia,MESH:D000708,,HIF1A,6.39
103D5R,C496879,"Aortic Valve, Calcification of",MESH:C562942,,AKT1,5.43
103D5R,C496879,"Arthritis, Experimental",MESH:D001169,,VEGFA,4.06
103D5R,C496879,"Arthritis, Juvenile",MESH:D001171,,MAPK1,3.79
103D5R,C496879,"Arthritis, Rheumatoid",MESH:D001172,,VEGFA,3.71
103D5R,C496879,Asthma,MESH:D001249,,VEGFA,3.7
103D5R,C496879,Astrocytoma,MESH:D001254,,HIF1A,4.81
103D5R,C496879,Ataxia,MESH:D001259,,SLC2A1,4.15
103D5R,C496879,Atherosclerosis,MESH:D050197,,VEGFA,3.76
103D5R,C496879,Atrophy,MESH:D001284,,MAPK3,3.77
103D5R,C496879,Autistic Disorder,MESH:D001321,,MAPK3,3.35
103D5R,C496879,Brain Injuries,MESH:D001930,,VEGFA,3.67
103D5R,C496879,Brain Ischemia,MESH:D002545,,HIF1A,14.21
103D5R,C496879,Brain Ischemia,MESH:D002545,,MAPK1,14.21
103D5R,C496879,Brain Ischemia,MESH:D002545,,MAPK3,14.21
103D5R,C496879,Brain Neoplasms,MESH:D001932,,VEGFA,4.28
103D5R,C496879,Breast Neoplasms,MESH:D001943,,AKT1,9.76
103D5R,C496879,Breast Neoplasms,MESH:D001943,,HIF1A,9.76
103D5R,C496879,Breast Neoplasms,MESH:D001943,,SLC2A1,9.76
103D5R,C496879,"Bronchitis, Chronic",MESH:D029481,,VEGFA,4.6
103D5R,C496879,Carcinogenesis,MESH:D063646,,AKT1,4.35
103D5R,C496879,Carcinoma,MESH:D002277,,HIF1A,3.89
103D5R,C496879,"Carcinoma, Ductal",MESH:D044584,,HIF1A,13.19
103D5R,C496879,"Carcinoma, Ductal",MESH:D044584,,SLC2A1,13.19
103D5R,C496879,"Carcinoma, Hepatocellular",MESH:D006528,,AKT1,6.52
103D5R,C496879,"Carcinoma, Hepatocellular",MESH:D006528,,SLC2A1,6.52
103D5R,C496879,"Carcinoma, Intraductal, Noninfiltrating",MESH:D002285,,HIF1A,15.1
103D5R,C496879,"Carcinoma, Intraductal, Noninfiltrating",MESH:D002285,,SLC2A1,15.1
103D5R,C496879,"Carcinoma, Non-Small-Cell Lung",MESH:D002289,,HIF1A,8.42
103D5R,C496879,"Carcinoma, Non-Small-Cell Lung",MESH:D002289,,VEGFA,8.42
103D5R,C496879,"Carcinoma, Pancreatic Ductal",MESH:D021441,,VEGFA,4.69
103D5R,C496879,"Carcinoma, Renal Cell",MESH:D002292,,SLC2A1,4.32
103D5R,C496879,"Carcinoma, Squamous Cell",MESH:D002294,,AKT1,19.59
103D5R,C496879,"Carcinoma, Squamous Cell",MESH:D002294,,MAPK1,19.59
103D5R,C496879,"Carcinoma, Squamous Cell",MESH:D002294,,MAPK3,19.59
103D5R,C496879,"Carcinoma, Squamous Cell",MESH:D002294,,VEGFA,19.59
103D5R,C496879,Cardiomegaly,MESH:D006332,,AKT1,7.84
103D5R,C496879,Cardiomegaly,MESH:D006332,,HIF1A,7.84
103D5R,C496879,Cardiomyopathies,MESH:D009202,,AKT1,12.38
103D5R,C496879,Cardiomyopathies,MESH:D009202,,MAPK1,12.38
103D5R,C496879,Cardiomyopathies,MESH:D009202,,MAPK3,12.38
103D5R,C496879,"Cell Transformation, Neoplastic",MESH:D002471,,HIF1A,17.96
103D5R,C496879,"Cell Transformation, Neoplastic",MESH:D002471,,MAPK8,17.96
103D5R,C496879,"Cell Transformation, Neoplastic",MESH:D002471,,SLC2A1,17.96
103D5R,C496879,"Cell Transformation, Neoplastic",MESH:D002471,,VEGFA,17.96
103D5R,C496879,Cerebral Hemorrhage,MESH:D002543,,VEGFA,4.04
103D5R,C496879,"Ceroid Lipofuscinosis, Neuronal, 6",MESH:C566627,,MAPK1,12.89
103D5R,C496879,"Ceroid Lipofuscinosis, Neuronal, 6",MESH:C566627,,MAPK3,12.89
103D5R,C496879,Chemical and Drug Induced Liver Injury,MESH:D056486,,VEGFA,2.82
103D5R,C496879,"Cholangitis, Sclerosing",MESH:D015209,,HIF1A,5.11
103D5R,C496879,"Cholestasis, Extrahepatic",MESH:D001651,,MAPK1,18.4
103D5R,C496879,"Cholestasis, Extrahepatic",MESH:D001651,,MAPK3,18.4
103D5R,C496879,"Cholestasis, Extrahepatic",MESH:D001651,,MAPK8,18.4
103D5R,C496879,"Choreoathetosis-Spasticity, Episodic",MESH:C563401,,SLC2A1,6.61
103D5R,C496879,Choroidal Neovascularization,MESH:D020256,,VEGFA,5.86
103D5R,C496879,Clear-cell metastatic renal cell carcinoma,MESH:C538445,,VEGFA,5.74
103D5R,C496879,Cocaine-Related Disorders,MESH:D019970,,MAPK1,7.16
103D5R,C496879,Cocaine-Related Disorders,MESH:D019970,,MAPK3,7.16
103D5R,C496879,Colonic Neoplasms,MESH:D003110,,SLC2A1,7.84
103D5R,C496879,Colonic Neoplasms,MESH:D003110,,VEGFA,7.84
103D5R,C496879,Colorectal Neoplasms,MESH:D015179,,AKT1,3.38
103D5R,C496879,Corneal Neovascularization,MESH:D016510,,VEGFA,5.74
103D5R,C496879,Coronary Artery Disease,MESH:D003324,,VEGFA,3.95
103D5R,C496879,Coronavirus Infections,MESH:D018352,,MAPK1,11.72
103D5R,C496879,Coronavirus Infections,MESH:D018352,,MAPK3,11.72
103D5R,C496879,COWDEN SYNDROME 6,OMIM:615109,,AKT1,6.4
103D5R,C496879,"Cryohydrocytosis, Stomatin-Deficient, with Mental Retardation, Seizures, Cataracts, and Massive Hepatosplenomegaly",MESH:C563840,,SLC2A1,6.95
103D5R,C496879,"Dermatitis, Atopic",MESH:D003876,,MAPK8,4.22
103D5R,C496879,"Dermatitis, Contact",MESH:D003877,,VEGFA,3.94
103D5R,C496879,Developmental Disabilities,MESH:D002658,,MAPK3,10.35
103D5R,C496879,Developmental Disabilities,MESH:D002658,,SLC2A1,10.35
103D5R,C496879,Diabetes Complications,MESH:D048909,,HIF1A,10.65
103D5R,C496879,Diabetes Complications,MESH:D048909,,VEGFA,10.65
103D5R,C496879,"Diabetes Mellitus, Experimental",MESH:D003921,,VEGFA,3.78
103D5R,C496879,"Diabetes Mellitus, Type 2",MESH:D003924,,AKT1,7.72
103D5R,C496879,"Diabetes Mellitus, Type 2",MESH:D003924,,SLC2A1,7.72
103D5R,C496879,Diabetic Nephropathies,MESH:D003928,,VEGFA,4.02
103D5R,C496879,Diabetic Retinopathy,MESH:D003930,,VEGFA,4.68
103D5R,C496879,"Disease Models, Animal",MESH:D004195,,AKT1,16.59
103D5R,C496879,"Disease Models, Animal",MESH:D004195,,MAPK1,16.59
103D5R,C496879,"Disease Models, Animal",MESH:D004195,,MAPK3,16.59
103D5R,C496879,"Disease Models, Animal",MESH:D004195,,MAPK8,16.59
103D5R,C496879,Disease Progression,MESH:D018450,,HIF1A,3.91
103D5R,C496879,Drug-Related Side Effects and Adverse Reactions,MESH:D064420,,VEGFA,3.27
103D5R,C496879,Endometrial Neoplasms,MESH:D016889,,VEGFA,4.15
103D5R,C496879,Epilepsy,MESH:D004827,,AKT1,3.67
103D5R,C496879,"Epilepsy, Temporal Lobe",MESH:D004833,,VEGFA,4.63
103D5R,C496879,Erectile Dysfunction,MESH:D007172,,VEGFA,4.04
103D5R,C496879,Esophageal Squamous Cell Carcinoma,MESH:D000077277,,HIF1A,4.38
103D5R,C496879,Fatty Liver,MESH:D005234,,AKT1,3.34
103D5R,C496879,Fibrosis,MESH:D005355,,AKT1,3.49
103D5R,C496879,Glioblastoma,MESH:D005909,,HIF1A,9.1
103D5R,C496879,Glioblastoma,MESH:D005909,,VEGFA,9.1
103D5R,C496879,Gliosarcoma,MESH:D018316,,VEGFA,5.45
103D5R,C496879,Gliosis,MESH:D005911,,MAPK1,9.41
103D5R,C496879,Gliosis,MESH:D005911,,MAPK3,9.41
103D5R,C496879,Glut1 Deficiency Syndrome,MESH:C536830,,SLC2A1,6.95
103D5R,C496879,GLUT1 DEFICIENCY SYNDROME 2,OMIM:612126,,SLC2A1,6.95
103D5R,C496879,Head and Neck Neoplasms,MESH:D006258,,MAPK1,17.29
103D5R,C496879,Head and Neck Neoplasms,MESH:D006258,,MAPK3,17.29
103D5R,C496879,Head and Neck Neoplasms,MESH:D006258,,VEGFA,17.29
103D5R,C496879,"Heart Defects, Congenital",MESH:D006330,,HIF1A,9.19
103D5R,C496879,"Heart Defects, Congenital",MESH:D006330,,VEGFA,9.19
103D5R,C496879,Heart Diseases,MESH:D006331,,VEGFA,3.52
103D5R,C496879,Heart Failure,MESH:D006333,,HIF1A,7.07
103D5R,C496879,Heart Failure,MESH:D006333,,VEGFA,7.07
103D5R,C496879,Hemangioblastoma,MESH:D018325,,HIF1A,5.93
103D5R,C496879,Hemangiosarcoma,MESH:D006394,,VEGFA,4.57
103D5R,C496879,Hemorrhage,MESH:D006470,,VEGFA,3.59
103D5R,C496879,Hepatomegaly,MESH:D006529,,AKT1,3.24
103D5R,C496879,Hodgkin Disease,MESH:D006689,,MAPK1,4.02
103D5R,C496879,Hyperalgesia,MESH:D006930,,MAPK1,11.15
103D5R,C496879,Hyperalgesia,MESH:D006930,,MAPK3,11.15
103D5R,C496879,Hyperalgesia,MESH:D006930,,MAPK8,11.15
103D5R,C496879,Hyperplasia,MESH:D006965,,AKT1,7.86
103D5R,C496879,Hyperplasia,MESH:D006965,,HIF1A,7.86
103D5R,C496879,Hypertension,MESH:D006973,,HIF1A,3.28
103D5R,C496879,"Hypertension, Portal",MESH:D006975,,VEGFA,4.67
103D5R,C496879,"Hypertension, Pulmonary",MESH:D006976,,HIF1A,4.17
103D5R,C496879,Hypertriglyceridemia,MESH:D015228,,AKT1,3.94
103D5R,C496879,Hypertrophy,MESH:D006984,,MAPK1,8.86
103D5R,C496879,Hypertrophy,MESH:D006984,,MAPK3,8.86
103D5R,C496879,"Hypoxia-Ischemia, Brain",MESH:D020925,,HIF1A,12.73
103D5R,C496879,"Hypoxia-Ischemia, Brain",MESH:D020925,,VEGFA,12.73
103D5R,C496879,Idiopathic Pulmonary Fibrosis,MESH:D054990,,HIF1A,5.09
103D5R,C496879,"Infertility, Female",MESH:D007247,,MAPK1,9.44
103D5R,C496879,"Infertility, Female",MESH:D007247,,MAPK3,9.44
103D5R,C496879,Inflammation,MESH:D007249,,AKT1,6.27
103D5R,C496879,Inflammation,MESH:D007249,,VEGFA,6.27
103D5R,C496879,Intellectual Disability,MESH:D008607,,SLC2A1,4.41
103D5R,C496879,Kidney Neoplasms,MESH:D007680,,MAPK1,8.84
103D5R,C496879,Kidney Neoplasms,MESH:D007680,,MAPK3,8.84
103D5R,C496879,Learning Disabilities,MESH:D007859,,VEGFA,3.67
103D5R,C496879,"Leukemia, Myeloid",MESH:D007951,,VEGFA,4.58
103D5R,C496879,"Leukemia, Promyelocytic, Acute",MESH:D015473,,AKT1,4.06
103D5R,C496879,Liver Cirrhosis,MESH:D008103,,HIF1A,7.74
103D5R,C496879,Liver Cirrhosis,MESH:D008103,,VEGFA,7.74
103D5R,C496879,"Liver Cirrhosis, Biliary",MESH:D008105,,HIF1A,4.58
103D5R,C496879,"Liver Cirrhosis, Experimental",MESH:D008106,,VEGFA,3.13
103D5R,C496879,Liver Failure,MESH:D017093,,VEGFA,4.22
103D5R,C496879,"Liver Failure, Acute",MESH:D017114,,MAPK8,3.98
103D5R,C496879,Liver Neoplasms,MESH:D008113,,SLC2A1,3.85
103D5R,C496879,"Liver Neoplasms, Experimental",MESH:D008114,,MAPK1,7.3
